Clinical Trial

DETACT sEvere asThmAtiC paTients - a Pilot Study

Study acronym: DETACT
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 17, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The objective of this study is to investigate the effect of dupilumab treatment on mucus plugging in severe asthma patients with severe eosinophilic asthma. Therefore, the investigators plan to apply computer tomography to investigate mucus plugging and thoroughly examine different airway samples from Type 2-high severe asthmatic patients at a cellular, molecular, microbiological and metabolomic level. This study will help to unravel underlying treatment mechanisms of dupilumab therapy in severe asthmatics.
Trial Details
NCT Number NCT07025200
Lead Sponsor Medical University of Vienna
Conditions Asthma
Enrollment 10 participants
Start Date 2023-02-16
Primary Completion 2026-06 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-06-17